参七脑康胶囊联合依达拉奉治疗急性脑梗死的临床研究  

Clinical study on Shenqi Naokang Capsules combined with edaravone in treatment of acute cerebral infarction

作　　者：王超 丁俊杰[2] 王博[3] 涂小峰 WANG Chao;DING Jun-jie;WANG Bo;TU Xiao-feng(Zhengzhou Emergency Medical Rescue Center,Zhengzhou 450016,China;Department of Emergency,People’s Hospital of Zhengzhou,Zhengzhou 450003,China;Department of Neurosurgery,People’s Hospital of Zhengzhou,Zhengzhou 450003,China;Department of Emergency,the 7 th People’s hospital of Zhengzhou,Zhengzhou 450003,China)

机构地区：[1]郑州市紧急医疗救援中心,河南郑州450016 [2]郑州人民医院急诊科,河南郑州450003 [3]郑州人民医院神经外科,河南郑州450003 [4]郑州市第七人民医院急诊科,河南郑州450003

出　　处：《现代药物与临床》2022年第2期296-300,共5页Drugs & Clinic

基　　金：河南省医学科技攻关计划项目(LHGJ20200737)。

摘　　要：目的观察参七脑康胶囊联合依达拉奉注射液治疗急性脑梗死的临床疗效。方法选取2019年3月—2021年3月郑州人民医院收治的100例急性脑梗死住院患者,根据入院奇偶顺序将患者分为对照组和治疗组,每组各50例。对照组静脉滴注依达拉奉注射液,30 mg依达拉奉注射液用0.9%氯化钠溶液100 m L稀释,半小时内滴注结束,1次/d。治疗组在对照组治疗基础上口服参七脑康胶囊,4粒/次,3次/d。两组均治疗2周。观察两组临床疗效,比较两组治疗前后的Barthel指数评分量表(ADL)评分、美国国立卫生研究院脑卒中量表(NIHSS)评分、血液流变学指标、血清因子。结果治疗后,与对照组的总有效率78.00%相比,治疗组的总有效率94.00%明显更高(P<0.05)。治疗后,两组患者NIHSS评分下降,ADL评分升高(P<0.05),且治疗组的NIHSS评分低于对照组,ADL评分高于对照组(P<0.05)。治疗后,两组患者全血高切黏度(HBV)、纤维蛋白原(FIB)、全血低切黏度(LBV)水平均下降(P<0.05),且治疗组的HBV、FIB、LBV水平下降程度相对对照组更明显(P<0.05)。治疗后,两组患者神经元特异性烯醇化酶(NSE)、血管内皮细胞生长因子(VEGF)、S-100β水平均下降(P<0.05),且治疗组的NSE、VEGF、S-100β水平下降程度相对对照组更明显(P<0.05)。结论参七脑康胶囊联合依达拉奉注射液治疗急性脑梗死患者可有效减轻神经功能损伤,改善患者生活自理能力,同时调节机体血液流变学和血清NSE、VEGF、S-100β水平,具有较好的临床应用价值。Objective To observe the clinical effect of Shenqi Naokang Capsules combined with Edaravone Injection in treatment of acute cerebral infarction.Methods Patients(100 cases)with acute cerebral infarction in People’s Hospital of Zhengzhou from March 2019 to March 2021 were divided into control and treatment groups according to the odd-even order of admission,and each group had 50 cases.Patients in the control group were iv administered with Edaravone Injection,30 mg added into 0.9%sodium chloride solution,end of infusion within half an hour,once daily.Patients in the treatment group were po administered with Shenqi Naokang Capsules on the basis of the control group,4 grains/time,three times daily.Patients in two groups were treated for 4 weeks.After treatment,the clinical efficacies were evaluated,and ADL scores,NIHSS scores,hemorheological indexes,and serum factors level in two groups were compared.Results After treatment,the total effective rate of 94.00%in the treatment group was significantly higher than that of 78.00%in the control group(P<0.05).After treatment,the NIHSS scores in two groups were decreased,but the ADL scores in two groups were increased(P<0.05).The NIHSS score in the treatment group was lower than that in the control group,but the ADL score was higher than that in the control group(P<0.05).After treatment,the levels of HBV,FIB,and LBV in two groups were decreased(P<0.05),and the levels of HBV,FIB,and LBV in the treatment group was higher than that in the control group(P<0.05).After treatment,the levels of NSE,VEGF,and S-100βin two groups were decreased(P<0.05),and the levels of NSE,VEGF,and S-100βin the treatment group was higher than that in the control group(P<0.05).Conclusion Shenqi Naokang Capsules combined with Edaravone Injection in the treatment of patients with acute cerebral infarction can effectively reduce nerve function injury,improve self-care ability,regulate hemorheology and the levels of NSE,VEGF,and S-100β,which has good clinical application value.

关 键 词：参七脑康胶囊 依达拉奉注射液 急性脑梗死 NIHSS评分 ADL评分 血液流变学指标 血清因子 

分 类 号：R971[医药卫生—药品]